NasdaqGS:INBXBiotechs
Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?
In July 2026, Inhibrx Biosciences entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding its credit facility to up to US$500.0 million, including an immediate US$100.0 million Term C Loan and potential Term D funding of up to US$225.0 million at the lenders' discretion.
As part of the new debt tranche, the company issued immediately exercisable warrants to Oxford to purchase 21,457 common shares at a US$93.21 strike price, aligning lenders’...